The cullin-RING ubiquitin ligase, CRL1 SKP2 , directing the degradation of the tumor suppressor p27, is a well validated drug target in a wide variety of human cancers. In this issue of Chemistry & Biology, Wu and colleagues describe first-in-class small molecule inhibitors of CRL1 SKP2 -mediated degradation of p27.
Protein kinases are prime targets in targeted cancer therapy. By sheer numbers, E3 ubiquitin ligases-enzymes that facilitate the final step of ubiquitin attachment to protein substrates, thus dispatching them to the proteasome for degradation-would seem to constitute an equally exciting target space. However, despite increasing understanding of the biochemistry and physiology of these enzymes, specific targeting of E3s with small molecules has remained frustratingly difficult. The main reason for this may be that, unlike kinases, E3s are not known to possess catalytic pockets that can be readily targeted by a small molecule inhibitor. Thus, development options are largely confined to disrupting protein-protein interactions, a proposition notoriously destined for failure, or so we thought.
Arguably, few E3s are better validated as potential cancer drug targets than CRL1 SKP2 (also known as SCF SKP2 ). CRL1 SKP2 is a member of the large family of cullin-RING ligases, multisubunit E3s consisting of a core complex of CUL1 and the RING domain protein RBX1 to which heterodimers of SKP1 and F-box containing substrate receptors are recruited ( Figure 1 ). One of these substrate receptors is SKP2, which, together with another small protein, CKS1, specifically recruits the cyclin-dependent kinase (CDK) inhibitor and tumor suppressor p27 KIP1 to mediate its polyubiquitylation and proteasomal degradation. Notably, SKP2 and CKS1 are frequently overexpressed in cancers, leading to ectopic p27 degradation, unrestrained proliferation, and poor patient prognosis (Chu et al., 2008) . For example, transgenic expression of SKP2 in the mouse prostate causes low-grade prostate carcinomas that coincide with p27 downregulation. Conversely, silencing of SKP2 expression inhibits tumor growth in various model systems. SKP2 À / À knockout mice are small and display general organ hypoplasia, phenotypes that are fully rescued by simultaneous deletion of p27. These findings validated CRL1 SKP2 as a formidable cancer drug target (Cardozo and Pagano, 2007) . Considering that virtually all normal differentiated cells express high levels of p27, compounds interfering with p27 degradation have a high potential for tumor specificity, thus promising a favorable safety profile.
Based on this rationale, several strategies have been developed to pharmacologically antagonize p27 degradation in cancer cells. These strategies vary widely in their specificity for p27 and, hence, in their predicted tolerability ( Figure 1 ). On one end of the spectrum are proteasome inhibitors such as bortezomib. While highly effective against multiple myeloma, dose limiting toxicities prevent the application of bortezomib in solid tumors. Likewise, the proteasome inhibitor Argyrin A has shown remarkable activity in driving p27-dependent cancer cell apoptosis in mouse models (Nickeleit et al., 2008) . Other agents broadly impacting on E3 activity include inhibitors of E1 ubiquitin activating enzyme (Brownell et al., 2010) . Higher specificity is afforded by CC0651, a recently discovered allosteric inhibitor of the E2 CDC34, which ubiquitylates p27 in concert with CRL1 SKP2 (Ceccarelli et al., 2011) . However, as expected, this compound also interferes with the degradation of other CDC34 substrates such as cyclin E. Similarly, MLN4924, a drug that inhibits attachment of the activating NEDD8 modification to cullins leads to accumulation of p27 but also many other CRL substrates (Soucy et al., 2009 ). Yet, a higher level of p27 specificity is afforded by compounds, which disrupt the interaction of SKP1 with SKP2 (Chen et al., 2008) , downregulate SKP2 expression (Rico-Bautista et al., 2010), or inhibit CDKs to prevent phosphorylationdependent binding of p27 to SKP2-CKS1. Again, in all three instances, additional substrates of SKP2 or CDKs would be expected to be affected by these regimens.
As far as specificity goes, Wu et al. (2012) , in this issue of Chemistry & Biology, have unearthed what appears to be no less than the Holy Grail of the pharmacologic targeting of CRL1 SKP2 : compounds that prevent the ubiquitylation and degradation of only a single class of substrates, p27 and the related CDK inhibitor p21 (and perhaps p57). The feat was achieved by focusing in silico screening on a phospho-p27 binding pocket uniquely formed by a complex between SKP2 and CKS1. As predicted by docking, the resultant compounds C1, 2, 16, and 20 (collectively dubbed ''SKPins'' for the purpose of this article) assume similar poses in their binding pocket, thereby disrupting critical interactions between phospho-p27 and SKP2-CKS1. SKPins show impressive selectivity for CRL1 SKP2mediated p27 degradation, neither impairing the activity of E1, E2, or other E3 enzymes (CRL1 b-TRCP , MDM2) nor causing stabilization of other SKP2 substrates. The latter finding can be rationalized by the strict dependency of the mechanism of action of SKPins on CKS1. Finally, the authors rule out possible inhibitory effects of SKPins on p27 phosphorylation. SKPin-mediated p27 stabilization is subsequently shown to inhibit cell cycle progression in various cancer cells lines in a p27 and SKP2dependent manner.
Although SKPins provide striking proofof-principle for the feasibility of targeting of CRL1-substrate interactions with small molecules, thinking ahead to a possible clinical application, several questions remain. For one, the in vitro cytotoxic activity of SKPins identified in melanoma and breast cancer cell lines was not referenced to ''normal,'' i.e., untransformed cells, thus rendering the cancer cell selectivity of the compounds uncertain. It also remains to be seen if the current hit series will be bioactive in humans or if suitable analogs can be developed. Likewise, the safety profile of SKPins is currently unknown because possible off-target effects have not been ruled out. The conceptual question of whether or not the upregulation of p27 in cancer cells bears risks connected with the cell migration promoting activity identified for cytoplasmically localized p27 is also unanswered. Finally, whereas SKPins were shown to exert their growth inhibitory function through SKP2 in the short run, it remains possible that parallel degradation pathways mediated by other p27-directed E3s such as PIRH2 and KPC will compensate for the loss of CRL1 SKP2 activity in the long run. Thus, while SKPins, unlike proteasome or NEDD8 E1 inhibitors, appear exquisitely specific for CRL1 SKP2 ; their very specificity may also compromise their longterm clinical efficacy due to the rapid enlistment of redundant pathways. As such, the true potential of SKPins (or more advanced analogs derived from them) may lie in their application as chemosensitizers to augment other cytostatic treatments.
Regardless, the current study highlights the power of structure-based approaches for chemical targeting of E3-substrate interactions. The same in silico strategy was effective in another case, identifying nutlins as inhibitors of the interaction of MDM2 with p53 (Vassilev et al., 2004) . With these two successes, structurebased approaches are emerging as promising avenues toward identifying pharmacophores able to revive other tumor suppressors that are frequently depleted by ectopic degradation, PTEN being a prominent one.
Figure 1. Strategies for Targeting p27 Degradation with Small Molecules
Small molecules targeting various steps in the p27 degradation pathway are indicated. The specificity of the inhibitors for p27 increases from right to left with SKPins, discovered in the work by Wu et al. (2012) , showing the highest specificity, directly disrupting the binding of phosphorylated p27 to the CRL1 substrate receptor unit formed by SKP2 and CKS1. p27 specificity is presumed to be inversely correlated with toxicity of the inhibitors. The antitumor efficacy in humans is unknown for most of the compounds listed with the exception of proteasome and neddylation inhibitors. Conceptually, the high specificity of SKPins for inhibiting p27 degradation appears to have a higher likelihood for redundancies that limit efficacy than less specific agents such as proteasome inhibitors. SMIP004, etc. refers to a group of compounds that downregulate SKP2 mRNA through complex mechanisms (Rico-Bautista et al., 2010) . For completeness, SMER3 references a compound that disrupts the interaction of SKP1 with the yeast CRL1 substrate receptor Met30 (Aghajan et al., 2010) .
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